CTLA4 and hepatocellular carcinoma: Recently, the FDA has approved the combination of Nivolumab with another checkpoint inhibitor, Ipilimumab that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), for treatment of patients with advanced HCC previously treated with Sorafenib 8.